Joseph Galanko
Appearances
- DateMay 7, 2023BACKGROUND: Novel treatment options for eosinophilic esophagitis (EoE) are needed. Previous studies have assessed mepolizumab (mepo), a monoclonal antibody against IL-5, with mixed results in EoE, and the efficacy of mepo in an adult and adolescent population has yet to be fully examined…
Presenter
University of North Carolina School of MedicineSpeakers
University of UtahUniversity of North Carolina at Chapel Hill School of Medicine - DateMay 7, 2023BACKGROUND: Novel treatment options for eosinophilic esophagitis (EoE) are needed. Previous studies have assessed mepolizumab (mepo), a monoclonal antibody against IL-5, with mixed results in EoE, and the efficacy of mepo in an adult and adolescent population has yet to be fully examined…
Presenter
University of North Carolina School of MedicineSpeakers
University of UtahUniversity of North Carolina at Chapel Hill School of Medicine - DateMay 8, 2023BACKGROUND: Tumor necrosis factor inhibitors (TNFi) are a mainstay of pediatric Crohn’s disease (PCD) therapy; yet not all patients respond, and others lose response over time. Combination therapy with methotrexate may improve response; however, this has not been rigorously evaluated…
